Cunningham, M.M.; Romero, R.; Alvarez, C.; Saxena Beem, S.; Schwartz, T.A.; Ishizawar, R.C.
Neutrophil to Lymphocyte Ratio as a Biomarker for the Prediction of Cancer Outcomes and Immune-Related Adverse Events in a CTLA-4-Treated Population. Cancers 2025, 17, 2011.
https://doi.org/10.3390/cancers17122011
AMA Style
Cunningham MM, Romero R, Alvarez C, Saxena Beem S, Schwartz TA, Ishizawar RC.
Neutrophil to Lymphocyte Ratio as a Biomarker for the Prediction of Cancer Outcomes and Immune-Related Adverse Events in a CTLA-4-Treated Population. Cancers. 2025; 17(12):2011.
https://doi.org/10.3390/cancers17122011
Chicago/Turabian Style
Cunningham, Michael M., Rachel Romero, Carolina Alvarez, Shruti Saxena Beem, Todd A. Schwartz, and Rumey C. Ishizawar.
2025. "Neutrophil to Lymphocyte Ratio as a Biomarker for the Prediction of Cancer Outcomes and Immune-Related Adverse Events in a CTLA-4-Treated Population" Cancers 17, no. 12: 2011.
https://doi.org/10.3390/cancers17122011
APA Style
Cunningham, M. M., Romero, R., Alvarez, C., Saxena Beem, S., Schwartz, T. A., & Ishizawar, R. C.
(2025). Neutrophil to Lymphocyte Ratio as a Biomarker for the Prediction of Cancer Outcomes and Immune-Related Adverse Events in a CTLA-4-Treated Population. Cancers, 17(12), 2011.
https://doi.org/10.3390/cancers17122011
